MX359825B - Compuesto pirazol y su uso farmaceutico. - Google Patents

Compuesto pirazol y su uso farmaceutico.

Info

Publication number
MX359825B
MX359825B MX2014002552A MX2014002552A MX359825B MX 359825 B MX359825 B MX 359825B MX 2014002552 A MX2014002552 A MX 2014002552A MX 2014002552 A MX2014002552 A MX 2014002552A MX 359825 B MX359825 B MX 359825B
Authority
MX
Mexico
Prior art keywords
medical purposes
pyrazole compound
formula
pyrazole
compound
Prior art date
Application number
MX2014002552A
Other languages
English (en)
Other versions
MX2014002552A (es
Inventor
Hiroshi Ueno
Kazuyuki Sugimoto
Kazuhito Ueyama
Yosuke Ogoshi
Dai Motoda
Tomoya Miura
Toshihiko Iwayama
Koichi Suzawa
Hironobu Nagamori
Akihiko Takahashi
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of MX2014002552A publication Critical patent/MX2014002552A/es
Publication of MX359825B publication Critical patent/MX359825B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de la siguiente Fórmula general [Ib]: (ver Fórmula) donde cada símbolo es el mismo como se definió en la descripción; o una de sus sales farmacéuticamente aceptables.
MX2014002552A 2011-08-31 2012-08-30 Compuesto pirazol y su uso farmaceutico. MX359825B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011188121 2011-08-31
US201161573433P 2011-09-06 2011-09-06
PCT/JP2012/072066 WO2013031922A1 (ja) 2011-08-31 2012-08-30 ピラゾール化合物及びその医薬用途

Publications (2)

Publication Number Publication Date
MX2014002552A MX2014002552A (es) 2014-04-25
MX359825B true MX359825B (es) 2018-10-10

Family

ID=47756400

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002552A MX359825B (es) 2011-08-31 2012-08-30 Compuesto pirazol y su uso farmaceutico.

Country Status (26)

Country Link
US (5) US8846746B2 (es)
EP (3) EP3524599A1 (es)
JP (5) JP6091811B2 (es)
KR (1) KR101989203B1 (es)
CN (1) CN103917535B (es)
AR (2) AR087701A1 (es)
AU (1) AU2012302723B2 (es)
BR (1) BR112014004651B1 (es)
CA (1) CA2845127C (es)
CL (1) CL2014000490A1 (es)
CO (1) CO6890098A2 (es)
CY (1) CY1121631T1 (es)
DK (1) DK3199533T3 (es)
HK (1) HK1202290A1 (es)
IL (1) IL230763A (es)
MX (1) MX359825B (es)
MY (1) MY172422A (es)
PE (1) PE20142343A1 (es)
PL (1) PL3199533T3 (es)
RS (1) RS58870B1 (es)
RU (1) RU2617678C2 (es)
SG (1) SG11201400244YA (es)
SI (1) SI3199533T1 (es)
TW (1) TWI549949B (es)
WO (1) WO2013031922A1 (es)
ZA (1) ZA201401071B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
UA117092C2 (uk) 2011-09-06 2018-06-25 Байєр Інтеллектуал Проперті Гмбх Амінозаміщені імідазопіридазини
ES2601127T3 (es) 2012-05-07 2017-02-14 Kissei Pharmaceutical Co., Ltd. Derivado de pirazol y su uso con fines médicos
JP2015537017A (ja) 2012-11-19 2015-12-24 バイエル ファーマ アクチエンゲゼルシャフト アミノイミダゾピリダジン類
US10022389B2 (en) * 2013-02-04 2018-07-17 Taisho Pharmaceutical Co., Ltd. Prophylactic or therapeutic drug for constipation
US9334307B2 (en) 2013-05-08 2016-05-10 The University Of Houston System Targeting the EGFR-SGLT1 interaction for cancer therapy
CN105294703B (zh) * 2015-10-23 2018-01-23 西安近代化学研究所 3,7,10‑三氧代‑2,4,6,8,9,11‑六氮杂[3,3,3]螺桨烷的合成方法
US20190166840A1 (en) 2016-08-11 2019-06-06 Bayer Cropscience Aktiengesellschaft Substituted pyrazolinyl derivatives, processes for their preparation and their use as herbicides and/or plant growth regulators
MX2019001813A (es) 2016-08-15 2019-05-20 Bayer Cropscience Ag Procedimiento para la preparacion de pyrazoles de 3-amino-1-(2,6-disustituido-fenilo).
TWI805699B (zh) * 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
WO2019194207A1 (ja) * 2018-04-04 2019-10-10 日本たばこ産業株式会社 ヘテロアリールで置換されたピラゾール化合物及びその医薬用途
EP4026564A4 (en) * 2019-09-04 2023-03-15 Japan Tobacco Inc. THERAPEUTIC OR PROPHYLACTIC PROCEDURE FOR DIABETES USING COMBINATION MEDICATION
JPWO2021045161A1 (es) * 2019-09-04 2021-03-11
CA3175131A1 (en) 2020-03-19 2021-09-23 Chihiro Okuma Treatment or prevention method for chronic heart failure

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2713225B1 (fr) 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
ES2249270T3 (es) * 1999-08-12 2006-04-01 Pharmacia Italia S.P.A. Derivados de 3(5)-aminopirazol, procedimiento para su preparacion y su uso como agentes antitumorales.
US6387900B1 (en) * 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
US8084467B2 (en) * 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
NZ538117A (en) * 2002-08-08 2007-01-26 Kissei Pharmaceutical Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
JP2004137245A (ja) * 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
DE102004028241B4 (de) 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
AR051446A1 (es) * 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
AP2007003979A0 (en) * 2004-11-23 2007-06-30 Warner Lambert Co 7-(2h-pyrazol-3-yl)-3,5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for thetreatment of lipidemia
WO2007034279A2 (en) 2005-09-19 2007-03-29 Pfizer Products Inc. C3a antagonists and pharmaceutical compositions thereof
TWI378922B (en) * 2005-10-21 2012-12-11 Mitsubishi Tanabe Pharma Corp A pyrazole compound
JP5069894B2 (ja) * 2005-10-21 2012-11-07 田辺三菱製薬株式会社 ピラゾール化合物
US7872006B2 (en) 2005-10-21 2011-01-18 Mitsubishi Tanabe Pharma Corporation Pyrazole compounds having cannabinoid receptor (CB1) antagonizing activity
US20070117858A1 (en) * 2005-11-23 2007-05-24 Mingde Xia Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators
EP2079728B1 (en) * 2006-10-10 2013-09-25 Amgen Inc. N-aryl pyrazole compounds for use against diabetes
JP4994295B2 (ja) * 2007-04-20 2012-08-08 田辺三菱製薬株式会社 医薬組成物
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
JP2010222298A (ja) * 2009-03-24 2010-10-07 Shionogi & Co Ltd Ｎｐｙｙ５受容体拮抗作用を有するピロリドン誘導体
US8278302B2 (en) * 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
US8163704B2 (en) * 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
CA2829790C (en) 2010-03-30 2018-06-05 Verseon Corporation Multisubstituted aromatic compounds as inhibitors of thrombin
CN105753858B (zh) 2010-07-02 2019-04-30 Aska制药株式会社 杂环化合物及p27Kip1分解抑制剂
CA2818903C (en) 2010-12-14 2021-03-23 Electrophoretics Limited 5-(1,3-benzoxazol-2-yl)-4-(pyridin-4-yl)pyrimidin-2-amine and its use as a casein kinase 1delta inhibitor
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1

Also Published As

Publication number Publication date
EP3199533B1 (en) 2019-02-27
EP3199533A1 (en) 2017-08-02
EP2784074A1 (en) 2014-10-01
US20230348438A1 (en) 2023-11-02
TW201321372A (zh) 2013-06-01
MY172422A (en) 2019-11-25
JP2017082005A (ja) 2017-05-18
TWI549949B (zh) 2016-09-21
JP6091811B2 (ja) 2017-03-08
JP2018115216A (ja) 2018-07-26
AU2012302723B2 (en) 2016-08-11
AU2012302723A1 (en) 2014-02-27
DK3199533T3 (da) 2019-05-20
MX2014002552A (es) 2014-04-25
CL2014000490A1 (es) 2014-08-22
JP2023087032A (ja) 2023-06-22
SI3199533T1 (sl) 2019-06-28
US8846746B2 (en) 2014-09-30
NZ620977A (en) 2016-02-26
US20150183763A1 (en) 2015-07-02
PE20142343A1 (es) 2015-01-29
IL230763A0 (en) 2014-03-31
IL230763A (en) 2016-10-31
CY1121631T1 (el) 2020-07-31
HK1202290A1 (en) 2015-09-25
CA2845127A1 (en) 2013-03-07
CA2845127C (en) 2020-03-10
RU2014112048A (ru) 2015-10-10
WO2013031922A1 (ja) 2013-03-07
JP2020125348A (ja) 2020-08-20
ZA201401071B (en) 2016-10-26
EP3524599A1 (en) 2019-08-14
EP2784074A4 (en) 2015-06-03
US20200317644A1 (en) 2020-10-08
CN103917535A (zh) 2014-07-09
KR101989203B1 (ko) 2019-06-13
PL3199533T3 (pl) 2019-09-30
JP2013063968A (ja) 2013-04-11
KR20140062048A (ko) 2014-05-22
RU2617678C2 (ru) 2017-04-26
US20180346449A1 (en) 2018-12-06
AR087701A1 (es) 2014-04-09
SG11201400244YA (en) 2014-10-30
CO6890098A2 (es) 2014-03-10
RS58870B1 (sr) 2019-08-30
AR123441A2 (es) 2022-11-30
US20130085132A1 (en) 2013-04-04
CN103917535B (zh) 2015-06-24
BR112014004651B1 (pt) 2021-08-31
BR112014004651A2 (pt) 2017-03-28

Similar Documents

Publication Publication Date Title
MX359825B (es) Compuesto pirazol y su uso farmaceutico.
MX2013012542A (es) Compuestos de amida y aplicacion farmaceutica para el mismo.
PH12015501993A1 (en) Pyrazole-amide compound and medicinal uses therefor
PH12015501328A1 (en) Meglumine salt of 6-flouro-3-hydroxy-2-pyrazine carboxamide
IN2015DN01035A (es)
MX2015002040A (es) Baricitinib deuterado.
PH12015502178A1 (en) Pyridinylpyrazoloquinoline compound
MY184306A (en) Compounds for the treatment and prophylaxis of respiratory syncytial virus disease
MX2015001246A (es) Ibrutinib deuterado.
MY163187A (en) Novel imidazo-oxazine compound or salt thereof
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
TW201144301A (en) Processes for preparing linezolid
MX346248B (es) Derivados de [1,2,3]triazol[4,5-d]pirimidina como agonistas de los agonistas del receptor canabinoide 2.
PH12015501088A1 (en) Dimeric compounds
SA517381678B1 (ar) مركبات داي هيدرو بيريميدين-2-أون واستخدامها الطبي
IN2012DN00765A (es)
GB201101517D0 (en) Receptor antagonists
MX2015015755A (es) Derivados de perhidroquinoxalina utiles como analgesicos.
GB201305247D0 (en) Amide Compounds
IN2014DN10669A (es)
MX2014003701A (es) Compuestos para el tratamiento y profilaxis de enfermedad por el virus sincitial respiratorio.
MX2012014796A (es) Proceso para preparar 4-hidroxipiridinas.
GB201020397D0 (en) Compounds
WO2011047530A8 (zh) 类胡萝卜素衍生物及其制备方法和应用
MX2013009456A (es) Compuestos de azufre aromaticos sustituidos y metodos para su uso.

Legal Events

Date Code Title Description
FG Grant or registration